AstraZeneca, in partnership with Secaro and ERM, is launching a Clean Heat Program to decarbonize industrial heat across its supply chain, aiming to reduce emissions and stabilize costs amid volatile natural gas prices. Industrial heat, a major source of emissions in pharmaceutical manufacturing, has been hard to decarbonize due to its complexity and cost, but recent geopolitical events have made clean alternatives economically viable. The program supports suppliers with data-driven pathways and financing options to adopt low-carbon heat solutions, enhancing supply chain resilience and reducing exposure to energy price shocks. This initiative reflects a strategic shift where clean heat is viewed not just as sustainability but as risk management and a competitive advantage.
AstraZeneca PLC will announce its Q2 2026 earnings on July 27, following a strong Q1 with 12.5% revenue growth to $15.29 billion. Key growth driver Enhertu saw a 39.4% year-over-year revenue increase, reaching $831 million, and recently gained EU app...
AstraZeneca has agreed to pay $600 million upfront and up to $1.5 billion total for global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer with a specific genetic mutation ...
AstraZeneca has agreed to pay $600 million upfront, with up to $900 million more based on milestones, to acquire global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer pati...
HSBC downgraded AstraZeneca from 'buy' to 'hold' following the failure of its Wainua phase III trial for a heart disease treatment, which missed its primary endpoint. This trial was a major part of HSBC's positive outlook, and its failure has led to ...
UBS maintains a 'buy' rating on AstraZeneca ahead of its Q2 results due on July 27, expecting solid performance but no increase in full-year guidance. The bank forecasts 2026 revenue of $63.3 billion and core earnings per share of $9.48, with a margi...
